Interaction Checker

Four protein kinase inhibitors now available on the interaction checker

Monday 13 November 2017

Bosutinib, dasatinib, nilotinib and ponatinib are now listed in the interaction checker as cancer drugs and interactions can be found with all the comedications.

• Bosutinib (Bosulif®) is a protein kinase inhibitor and is indicated for the treatment of chronic myeloid leukemia (BCR-ABL positive). 
• Dasatinib (Sprycel®) is a protein kinase inhibitor and is indicated for the treatment of chronic myeloid leukemia (BCR-ABL positive) and precursor cell lymphoblastic leukemia-lymphoma.
• Nilotinib (Tasigna®) is a protein kinase inhibitor and is indicated for the treatment of chronic myeloid leukemia (BCR-ABL positive).
• Ponatinib (Iclusig®) is a protein kinase inhibitor and is indicated for the treatment of chronic myeloid leukemia (BCR-ABL positive).

ENDORSED BY
Bopa